Jpmorgan Chase & CO Gossamer Bio, Inc. Transaction History
Jpmorgan Chase & CO
- $1.51 Trillion
- Q3 2025
A detailed history of Jpmorgan Chase & CO transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 194,369 shares of GOSS stock, worth $526,739. This represents 0.0% of its overall portfolio holdings.
Number of Shares
194,369
Previous 194,369
-0.0%
Holding current value
$526,739
Previous $511,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding GOSS
# of Institutions
180Shares Held
163MCall Options Held
8.11MPut Options Held
211K-
Nea Management Company, LLC Timonium, MD18.1MShares$49 Million2.97% of portfolio
-
Octagon Capital Advisors LP New York, NY17.1MShares$46.2 Million14.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$32.5 Million0.0% of portfolio
-
Arch Venture Management, LLC Chicago, IL8.06MShares$21.8 Million9.24% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA6.13MShares$16.6 Million6.11% of portfolio
About Gossamer Bio, Inc.
- Ticker GOSS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,954,000
- Market Cap $255M
- Description
- Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...